Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 6/20 | 0.47 |
| ▸ | LMNA | P02545 | 5/20 | 0.47 |
| ▸ | MEN1 | O00255 | 4/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 4/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | HTT | P42858 | 2/20 | 0.47 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.47 |
| ▸ | HPGD | P15428 | 1/20 | 0.47 |
| ▸ | CRHBP | P24387 | 1/20 | 0.47 |
| ▸ | CRHR2 | Q13324 | 1/20 | 0.47 |
| ▸ | ANO1 | Q5XXA6 | 8/20 | 0.42 |
| ▸ | FFAR2 | O15552 | 1/20 | 0.38 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.37 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.36 |
| ▸ | NPC1 | O15118 | 1/20 | 0.36 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20456588 | 1.00 | MAPT (0.47) | MAPTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL19973040 | 0.85 | MAPT (0.46) | MAPTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL19973041 | 0.85 | MAPT (0.46) | MAPTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL23801147 | 0.81 | ALDH1A1 (0.58) | MAPTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL23801148 | 0.81 | ALDH1A1 (0.58) | MAPTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL20819238 | 0.80 | MAPT (0.45) | MAPTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL20819239 | 0.80 | MAPT (0.45) | MAPTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL29424172 | 0.79 | CASP3 (0.39) | MAPTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL19986219 | 0.76 | MAPT (0.46) | MAPTLMNAMEN1KMT2AALDH1A1 | |
| SCHEMBL20466960 | 0.74 | ALDH1A1 (0.42) | MAPTLMNAMEN1KMT2AALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 11 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220356192-A1 | FUSED 1,4-DIAZEPINES AS BET PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2022-11-10 | — | — | US | disclosed |
| EP-3858837-A1 | FUSED 1,4-DIAZEPINES AS BET PROTEIN DEGRADERS | The Regents of The University of Michigan (US) | 2021-08-04 | — | — | EP | disclosed |
| US-11046709-B2 | Fused 1,4-diazepines as BET bromodomain inhibitors | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-06-29 | — | — | US | disclosed |
| US-10975093-B2 | Fused 1,4-diazepines as BET protein degraders | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2021-04-13 | — | — | US | disclosed |
| EP-3512853-B1 | FUSED 1,4-DIAZEPINES AS BET PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2020-12-23 | — | — | EP | disclosed |
| US-20200277305-A1 | BET Bromodomain Protein Degraders with Cleavable Linkers | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2020-09-03 | — | — | US | disclosed |
| US-20190263827-A1 | FUSED 1,4-DIAZEPINES AS BET PROTEIN DEGRADERS | UNIV MICHIGAN REGENTS (US) | 2019-08-29 | — | — | US | disclosed |
| EP-3512853-A1 | FUSED 1,4-DIAZEPINES AS BET PROTEIN DEGRADERS | The Regents of The University of Michigan (US) | 2019-07-24 | — | — | EP | disclosed |
| WO-2019055444-A1 | BET BROMODOMAIN PROTEIN DEGRADERS WITH CLEAVABLE LINKERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2019-03-21 | — | — | WO | disclosed |
| WO-2018144789-A1 | FUSED 1,4-DIAZEPINES AS BET BROMODOMAIN INHIBITORS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-08-09 | — | — | WO | disclosed |
| WO-2018052949-A1 | FUSED 1,4-DIAZEPINES AS BET PROTEIN DEGRADERS | THE REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2018-03-22 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200277305-A1 | BET Bromodomain Protein Degraders with Cleavable Linkers | BRD4, BET1, BRWD1 | MAPT 1300/4885LMNA 982/4885MEN1 1308/4885 |
| US-20190263827-A1 | FUSED 1,4-DIAZEPINES AS BET PROTEIN DEGRADERS | BRD4, BRD1, BET1 | MAPT 1379/4885LMNA 1572/4885MEN1 1847/4885 |
| US-11046709-B2 | Fused 1,4-diazepines as BET bromodomain inhibitors | BRD4, BRD3, BRD1 | MAPT 1483/4885LMNA 3320/4885MEN1 1856/4885 |
| US-10975093-B2 | Fused 1,4-diazepines as BET protein degraders | BRD4, BRD1, BET1 | MAPT 1379/4885LMNA 1572/4885MEN1 1847/4885 |
| US-20220356192-A1 | FUSED 1,4-DIAZEPINES AS BET PROTEIN DEGRADERS | BRD4, BRD1, BET1 | MAPT 1379/4885LMNA 1572/4885MEN1 1847/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.